ID   4434
AC   CVCL_E9CI
RX   PubMed=25873177;
CC   Sequence variation: Mutation; MGI; MGI:88190; Braf; Simple; p.Val637Glu (c.1910T>A); Zygosity=Heterozygous (PubMed=25873177).
CC   Genetic integration: Method=Transgenic mouse; Gene=MGI; MGI:1352467; Esr1 (Note=Ligand binding domain; with p.Gly525Arg. Fused to Cre = CreERT2).
CC   Breed/subspecies: C57BL/6 BRAF+/LSL-BRAFV600E;Tyr::CreERT2+/o transgenic.
DI   NCIt; C21790; Mouse melanoma
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 14-08-25; Last updated: 14-08-25; Version: 1
//
RX   PubMed=25873177; DOI=10.1016/j.ccell.2015.03.008; PMCID=PMC4402404;
RA   Hirata, Eishu
RA   Girotti, Maria Romina
RA   Viros, Amaya
RA   Hooper, Steven
RA   Spencer-Dene, Bradley
RA   Matsuda, Michiyuki
RA   Larkin, James
RA   Marais, Richard
RA   Sahai, Erik
RT   "Intravital imaging reveals how BRAF inhibition generates
RT   drug-tolerant microenvironments with high integrin beta1/FAK
RT   signaling.";
RL   Cancer Cell 27:574-588(2015).
//